structurebas
drug
design
sbdd
emerg
valuabl
pharmaceut
lead
discoveri
tool
show
potenti
acceler
discoveri
process
reduc
development
cost
boost
potenc
drug
ultim
select
sbdd
iter
ration
lead
compound
sculpt
process
involv
synthesi
new
deriv
evalu
bind
target
structur
either
comput
dock
elucid
target
structur
complex
lead
compound
method
heavili
reli
product
highresolut
threedimension
structur
drug
target
obtain
xray
crystallograph
analysi
presenc
absenc
drug
candid
lack
gener
method
high
qualiti
crystal
product
still
major
bottleneck
process
macromolecular
crystal
review
provid
brief
introduct
sbdd
describ
sever
macromolecular
crystal
strategi
emphasi
advanc
challeng
face
research
field
today
recent
trend
develop
univers
macromolecular
crystal
techniqu
particularli
nucleationbas
techniqu
applic
solubl
integr
membran
protein
also
discuss
identif
promis
lead
compound
earli
drug
discoveri
process
critic
reduc
time
requir
optim
lead
initi
discoveri
potenti
hit
time
requir
develop
drug
lead
discoveri
final
form
typic
year
result
total
development
cost
exceed
billion
emphas
need
new
experiment
approach
streamlin
process
although
signific
advanc
made
use
librarybas
screen
strategi
new
lead
identif
becom
increasingli
clear
sbdd
even
greater
potenti
acceler
time
market
new
pharmaceut
entiti
significantli
reduc
cost
develop
sbdd
process
iter
approach
base
threedimension
structur
target
guid
develop
drug
lead
figur
method
util
comput
analysi
targetlead
complementar
use
threedimension
structur
target
targetlead
complex
favor
unfavor
lipophil
hydrogenbond
polar
interact
targetlead
complex
identifi
structur
refin
lead
often
emerg
targetlead
complex
crystal
analysi
result
highresolut
xray
structur
altern
approach
ie
virtual
screen
util
molecular
dock
simul
screen
librari
potenti
small
molecul
lead
estim
biolog
activ
success
drug
candid
regardless
initi
approach
pharmaceut
properti
lead
compound
eg
log
p
bioavail
metabol
toxic
pharmacokinet
structureact
relationship
potenc
etc
continu
optim
drug
candid
identifi
clinic
evalu
prime
exampl
sbdd
process
histori
proteas
inhibitor
develop
proteas
critic
enzym
life
cycl
hiv
retroviru
caus
autoimmun
defici
syndrom
aid
sinc
elucid
structur
sbdd
strategi
led
introduct
three
firstgener
hiv
proteas
inhibitor
hoffmanla
roch
saquinavir
abbott
ritonavir
merck
inc
indinavir
well
sever
potent
inhibitor
recent
year
exampl
mahalingam
cowork
develop
seri
proteas
inhibitor
activ
time
potent
current
analog
structur
potent
inhibitor
cocrystal
proteas
shown
figur
agent
consider
potent
ec
nm
indinavir
ec
nm
potent
atazanavir
ec
nm
first
proteas
inhibitor
given
onceaday
basi
sbdd
clearli
acceler
process
drug
develop
hiv
treatment
sinc
fda
approv
drug
treatment
viral
infect
combin
structurebas
studi
infecti
diseas
result
introduct
activ
drug
market
includ
sever
acut
respiratori
syndrom
sar
influenza
viru
sinc
sbdd
process
power
begin
atom
resolv
structur
target
essenti
develop
reliabl
rapid
predict
method
obtain
inform
enabl
develop
highli
potent
drug
candid
structur
elucid
protein
target
obtain
either
xray
crystallographi
nuclear
magnet
reson
nmr
techniqu
howev
protein
target
use
sbdd
obtain
use
xray
crystallographi
despit
capac
solv
structur
atom
resolut
practic
limit
xray
crystallographi
costeffect
wide
use
tool
howev
structur
determin
rate
ultim
resolut
govern
abil
grow
larg
diffract
qualiti
crystal
bottleneck
illustr
anoth
drawback
xray
method
ie
larg
amount
protein
requir
enabl
screen
mani
crystal
condit
discov
capabl
produc
highqual
singl
crystal
structur
protein
approxim
kd
determin
solut
use
techniqu
nuclear
overhaus
enhanc
spectroscopi
noesi
observ
interact
hydrogen
atom
close
proxim
apart
within
polypeptid
backbon
known
sequenc
process
laborintens
sinc
nand
cenrich
form
protein
must
express
order
resolv
overlap
peak
noesi
spectra
unfortun
neither
techniqu
highli
effect
elucid
membran
protein
structur
thu
far
sinc
less
nonredund
sequenc
deposit
pdb
june
membran
protein
especi
problemat
analysi
g
proteincoupl
receptor
gpcr
import
famili
membran
protein
involv
cellular
signal
encod
roughli
gene
known
function
repres
current
drug
target
drug
target
gpcr
known
year
cardiovascular
metabol
neurodegen
psychiatr
oncolog
diseas
even
though
molecular
detail
gpcr
famili
limit
elucid
human
adrenerg
receptor
ar
crystal
structur
highresolut
structur
enabl
rapid
develop
potent
arbas
therapeut
recent
studi
kolb
cowork
million
commerci
avail
leadlik
molecul
use
dock
screen
ar
highli
score
compound
screen
test
result
discoveri
six
new
inhibitor
bind
affin
one
k
nm
thu
highresolut
ar
structur
repres
signific
advanc
understand
util
structur
inform
gpcr
drug
discoveri
howev
mani
member
receptor
famili
whose
structur
remain
unsolv
situat
underscor
compel
need
new
strategi
aim
membran
protein
crystal
method
often
employ
macromolecular
crystal
either
highthroughput
platebas
screen
techniqu
microfluidicstyp
platform
use
autom
highthroughput
method
current
possibl
test
thousand
potenti
crystal
condit
set
monitor
trial
use
submicrolit
volum
protein
solut
miniatur
experi
reduc
labor
burden
devot
protein
express
purif
thu
enabl
evalu
crystal
trial
per
day
extrem
benefici
protein
target
labil
andor
avail
small
quantiti
microfluid
platform
also
use
reduc
volum
need
nl
per
crystal
condit
strategi
use
includ
determin
crystal
slot
osmot
second
virial
coeffici
b
lie
rang
molg
experiment
determin
rel
crystalliz
paramet
describ
percentag
crystal
nucleat
phase
area
within
protein
precipit
agent
concentr
rang
crystal
coeffici
c
proport
ratio
volum
diffus
rate
surfac
integr
rate
determin
kinet
crystal
window
c
crystal
grown
airwat
interfac
method
result
crystal
thousand
solubl
protein
howev
method
often
amen
membran
protein
crystal
reason
briefli
describ
protein
difficult
obtain
highli
pure
form
due
proteolyt
degrad
presenc
occult
impur
spite
advanc
made
increas
yield
membran
protein
express
proand
eukaryot
system
membran
protein
also
high
degre
conform
flexibl
often
produc
misfold
state
situat
exacerb
high
deterg
concentr
use
extract
purif
addit
display
complex
phase
diagram
convolut
presenc
deterg
endogen
membran
lipid
highli
sensit
solut
condit
eg
ph
salin
temperatur
etc
difficult
concentr
mild
condit
typic
yield
crystal
fragil
due
high
water
content
figur
illustr
differ
phase
diagram
zone
encount
crystal
process
inform
diagram
use
drive
transit
nucleat
zone
crystal
growth
occur
howev
phase
diagram
protein
unknown
often
lead
product
amorph
aggreg
crystallin
shower
instead
high
qualiti
singl
crystal
addit
sinc
crystal
process
batch
procedur
growth
larg
high
qualiti
crystal
challeng
protein
concentr
constantli
chang
growth
ensu
thu
product
high
qualiti
crystal
remain
major
stumbl
block
drug
discoveri
process
membran
protein
target
sbdd
spite
recent
advanc
made
acceler
rate
protein
structur
determin
approach
mention
major
impedi
remain
sinc
nucleat
first
step
crystal
process
develop
gener
method
control
protein
nucleat
could
help
reduc
bottleneck
protein
crystal
process
promis
approach
briefli
describ
import
method
base
bicontinu
cubic
phase
form
monooleinrich
dispers
led
success
crystal
sever
membran
protein
includ
ar
system
note
initi
report
landau
rosenbusch
crystal
bacteriorhodopsin
method
grow
crystal
simpli
involv
mix
two
part
solubil
protein
three
part
monoolein
produc
homogen
solut
lipid
cubic
phase
form
spontan
within
hour
week
occasion
requir
addit
precipit
attract
featur
cubic
phase
method
capac
retain
origin
phase
state
even
presenc
wide
array
polar
apolar
amphiphil
addit
caffrey
cowork
develop
famili
singl
chain
lipid
enabl
tailor
cubic
phase
microstructur
suit
requir
target
protein
howev
case
inform
known
precis
advanc
applic
method
instrument
grow
crystal
ar
highresolut
structur
describ
sligar
cowork
report
use
nanodisc
compris
bilay
membran
bound
ring
peptid
amphiphil
mean
solubil
stabil
membran
protein
solut
character
dispers
offer
potenti
assembl
nanodiscsolubil
membran
protein
order
array
suitabl
structur
analysi
method
offer
advantag
liposom
deterg
micel
due
stabil
small
size
abil
add
geneticallymodifi
featur
nanodisc
structur
accessiblilti
side
phospholipid
bilay
domain
nanodisc
use
success
reconstitut
membran
protein
structur
determin
high
resolut
solut
nmr
cryoelectron
microscopi
particl
reconstruct
although
potenti
use
nanod
protein
crystal
applic
still
unknown
rapid
advanc
made
thu
far
nanodisc
approach
suggest
tremend
potenti
advanc
field
membran
protein
structur
determin
sbdd
microfluidicsbas
approach
develop
ismagilov
cowork
creat
supersatur
protein
solut
within
converg
microfluid
channel
control
mix
buffer
protein
precipit
carrier
fluid
isol
protein
droplet
transport
microfluid
channel
produc
mix
induc
protein
nucleat
advantag
approach
abil
directli
load
crystal
grown
within
microfluid
channel
xray
capillari
diffract
analysi
crystal
exceed
length
grown
manner
solut
thaumatin
bovin
liver
catalas
glucos
isomeras
anoth
microfluidicsbas
approach
develop
keni
cowork
provid
control
extent
rate
protein
supersatur
vari
dimens
protein
evapor
chamber
multiwel
format
approach
consum
less
nl
materi
success
appli
crystal
bacteriorhodopsin
similar
approach
develop
ismagilov
cowork
util
fluorin
nitriliotriacet
acid
nta
amphiphil
specif
captur
histidinetag
protein
within
microfluid
channel
strategi
extend
histidinetag
protein
microfluid
devic
present
potenti
problem
howev
especi
solut
contain
deterg
amphiphil
crystal
membran
protein
surfac
properti
devic
care
control
surfact
molecul
could
inadvert
strip
membran
protein
dispers
therebi
alter
stabil
crystal
capac
devic
also
requir
integr
imag
system
capabl
monitor
crystal
condit
databas
manag
system
store
inform
collect
novel
seed
techniqu
recent
introduc
villasenor
cowork
use
acoust
wave
deliv
seed
suspens
protein
drop
techniqu
improv
upon
sparsematrix
screen
approach
reduc
chemic
bia
introduc
protein
droplet
reduc
volum
seed
suspens
nanolit
volum
author
also
discov
seed
techniqu
effect
increas
number
sparsematrix
condit
yield
protein
crystal
compar
buffer
addit
alon
particular
challeng
approach
seedinduc
crystal
may
occur
use
condit
without
seed
deem
unfavor
suggest
clear
correl
unproduct
protein
solut
good
seed
condit
although
uncertainti
make
challeng
know
one
close
success
crystal
condit
seed
method
clearli
demonstr
potenti
improv
yield
spars
matrix
condit
crystal
growth
interfaci
templat
strategi
use
variou
organ
eg
lipid
monolay
lipid
tubul
cubic
phase
inorgan
substrat
eg
gold
mica
develop
control
nucleat
twodimension
protein
crystal
review
interfaci
approach
see
ref
mirkin
cowork
demonstr
direct
growth
polypeptid
singl
crystal
use
dip
pen
nanolithographi
dpn
find
suggest
protein
crystal
growth
may
control
util
highli
period
substrat
nucleat
templat
laminar
flow
protein
target
templat
control
crystal
growth
rate
thompson
cowork
also
develop
noncoval
cyclodextrinbas
templat
util
revers
host
guest
chemistri
cyclodextrin
templat
ntamodifi
guest
ligand
captur
histidinetag
protein
among
advantag
techniqu
orient
protein
respect
templat
concentr
interfac
achiev
local
supersatur
revers
noncoval
bind
interfac
pseudoepitaxi
nucleat
crystal
highli
structur
surfac
small
grow
number
protein
crystal
use
interfaci
templat
approach
suggest
method
still
larg
untap
structur
elucid
sbdd
target
interfaci
templat
sitespecif
nucleat
strategi
emerg
power
tool
highthroughput
structur
determin
particularli
univers
rapid
predict
method
control
crystal
growth
merg
techniqu
stepwis
fashion
verdant
area
new
method
develop
creation
control
nucleat
crystal
techniqu
membran
protein
sbdd
unfortun
biochem
colloid
scienc
challeng
note
greatli
imped
progress
field
limit
rang
innov
new
strategi
attempt
understand
one
hand
effort
tightli
focus
structur
elucid
small
batch
newlyisol
function
purifi
membran
protein
unlik
spent
explor
novel
techniqu
due
high
valu
target
nonetheless
slow
progress
field
directli
attribut
overli
narrow
focu
consequ
still
great
need
design
develop
new
materi
process
embodi
mani
featur
outlin
possibl
util
vitro
express
system
minim
complex
sampl
remov
mani
nontarget
protein
contamin
possibl
develop
improv
deterg
whose
phase
diagram
map
respect
surfact
concentr
biomembran
compon
ionic
strength
ph
temperatur
commonli
use
precipit
nonaggress
deterg
strip
method
enabl
gradual
remov
amphiphil
avoid
commonli
encount
problem
like
precipit
crystal
shower
experimentallycontrol
site
rate
nucleat
guid
format
singl
larg
crystal
diffractioncompat
substrat
rather
shower
small
crystal
due
heterogen
nucleat
event
migrat
crystal
scheme
batchwis
process
flowbas
strategi
precis
transit
protein
solut
supersatur
regim
enabl
crystal
growth
rate
control
maintain
solut
composit
avoid
concentrationlimit
growth
larg
crystal
diffract
analysi
continu
emphasi
sampl
volum
reduct
reliev
burden
express
purif
system
expand
number
membran
protein
target
amen
xray
diffract
structur
elucid
increas
accept
rate
novel
methodolog
approach
structur
biologist
realiz
design
address
constraint
destin
acceler
drug
discoveri
process
improv
effici
univers
macromolecular
crystal
techniqu
particularli
membran
protein
lead
faster
structur
determin
potenti
drug
target
sbdd
identif
drug
target
structur
drugbind
site
determin
highest
resolut
possibl
atom
resolv
structur
enabl
rapid
refin
lead
compound
optim
drug
candid
left
ribbon
structur
proteas
complex
depict
space
fill
model
right
detail
proteaseinhibitor
complex
illustr
import
contact
conform
fit
protein
target
structur
reveal
bind
interact
depend
upon
homodimer
protein
provid
insight
design
nextgener
inhibitor
enhanc
bind
interact
reliabl
method
map
transit
supersatur
zone
dark
blue
nucleat
occur
metast
zone
light
blue
nucleat
begin
typic
unknown
sbdd
target
addit
protein
solut
composit
physic
factor
sampl
temperatur
influenc
avail
phase
space
crystal
nucleat
growth
